DZ Bank Reiterates Buy Rating for Bayer (BAYN)

Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by equities researchers at DZ Bank in a research note issued on Monday.

BAYN has been the topic of a number of other research reports. UBS set a €125.00 ($148.81) price objective on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, August 29th. S&P Global set a €126.00 ($150.00) price objective on shares of Bayer and gave the stock a “buy” rating in a research note on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) price objective on shares of Bayer and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Independent Research set a €120.00 ($142.86) price objective on shares of Bayer and gave the stock a “neutral” rating in a research note on Wednesday, August 23rd. Finally, equinet set a €118.00 ($140.48) price target on shares of Bayer and gave the stock a “buy” rating in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of €122.19 ($145.46).

Get Bayer AG alerts:

Bayer (FRA:BAYN) traded up €0.45 ($0.54) during trading hours on Monday, hitting €105.15 ($125.18). 1,560,433 shares of the stock were exchanged. Bayer has a 1 year low of €93.07 ($110.80) and a 1 year high of €123.82 ($147.40).

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/11/dz-bank-reiterates-buy-rating-for-bayer-bayn.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.